X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Following a competitive auction process, Tolmar was selected as the winning bidder in the sale of JATENZO (testosterone undecanoate), and the sale was approved by the U.S. Bankruptcy Court for the District of Delaware.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Jatenzo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Clarus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 27, 2022
Details:
Under terms of the agreement, Tolmar’s sales force will promote ALKINDI SPRINKLE® to their pediatric endocrinology targets alongside FENSOLVI®. ALKINDI SPRINKLE® (hydrocortisone) oral granules is FDA-approved as replacement therapy for Adrenocortical Insufficiency (AI).
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Alkindi Sprinkle
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eton Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 15, 2021
Details:
Throughout the transition, Sanofi Canada and Tolmar are collaborating fully to help ensure smooth transfer of the product and services for patients and healthcare providers, including the ELIGARD® Home Injection Program in place in Canada.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Eligard
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 08, 2021
Details:
The Company's lead product, ELIGARD®, is a luteinizing hormone releasing hormone (LHRH) agonist indicated for the treatment of advanced prostate cancer.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Endocrinology Product Name: Eligard
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Astellas Europe will return the in-licensing rights to “Eligard (leuprolide acetate for injectable suspension)” a treatment for advanced prostate cancer sold by Astellas Europe in Europe, the Middle East, the Commonwealth of Independent States (CIS)1 , and Asia, to Tolmar.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Eligard
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 01, 2021
Details:
Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Eligard
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Recordati
Deal Size: $168.6 million Upfront Cash: $42.1 million
Deal Type: Licensing Agreement January 29, 2021
Details:
The study evaluated 45-mg subcutaneous leuprolide acetate administered at a 6-month interval in 64 GnRHa-naïve children with CPP. Fensolvi effectively suppressed reproductive hormones and stopped or caused regression of pubertal progression.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Endocrinology Product Name: Fensolvi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
